Clostridium difficile--more difficult than ever.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  New England Journal of Medicine

• Publication date

  2008-10-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMra0707500PMID 18971494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clindamycin-associated colitis

  2020cited by this paper
• Results of a phase Iii trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea

  2008cited by this paper
• A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

  2007cited by this paper
• Probiotics for Clostridium difficile–Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii

  2007cited by this paper
• Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.

  2007cited by this paper
• Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea.

  2007cited by this paper
• Autocatalytic cleavage of Clostridium difficile toxin B

  2007cited by this paper
• Intravenous Immunoglobulin for the Treatment of Severe, Refractory, and Recurrent Clostridium difficile Diarrhea

  2006cited by this paper
• The Second International Conference on Women and Infectious Diseases

  2006cited by this paper
• Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

  2006cited by this paper
• Molecular Analysis of Clostridium difficile PCR Ribotype 027 Isolates from Eastern and Western Canada

  2006cited by this paper
• Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease

  2006cited by this paper
• Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters.

  2006cited by this paper
• Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–2003

  2006cited by this paper
• Emerging Therapies in the Treatment of Clostridium difficile–Associated Disease

  2006cited by this paper
• Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.

  2005cited by this paper
• Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

  2005cited by this paper
• Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

  2005cited by this paper
• Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains.

  2005cited by this paper
• A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

  2005cited by this paper
• An epidemic, toxin gene-variant strain of Clostridium difficile.

  2005cited by this paper
• Treatment of Clostridium difficile-associated disease: old therapies and new strategies.

  2005cited by this paper
• Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005.

  2005cited by this paper
• A Large Outbreak of Clostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use

  2005cited by this paper
• Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

  2005cited by this paper
• Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

  2005cited by this paper
• Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

  2004cited by this paper
• Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins

  2004cited by this paper
• Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea.

  2004cited by this paper
• Pathogenicity of Clostridium difficile Toxins

  2003cited by this paper
• Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube.

  2003cited by this paper
• Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature.

  2002cited by this paper
• Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis

  2002cited by this paper
• Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

  2002cited by this paper
• Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

  2001cited by this paper
• Clostridium difficile-associated diarrhea and colitis.

  2001cited by this paper
• Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults

  2001cited by this paper
• Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

  2000cited by this paper
• Colonization for the prevention of Clostridium difficile disease in hamsters.

  1999cited by this paper
• Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

  1998cited by this paper
• Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

  1997cited by this paper
• Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin.

  1995cited by this paper
• Clostridium Difficile-Associated Diarrhea and Colitis

  1995cited by this paper
• Decrease in Nosocomial Clostridium difficileAssociated Diarrhea by Restricting Clindamycin Use

  1994cited by this paper
• A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

  1994cited by this paper
• Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

  1992cited by this paper
• Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.

  1991cited by this paper
• Treatment of relapsingClostridium difficile diarrhoea by administration of a non-toxigenic strain

  1987cited by this paper
• An epidemic of pseudomembranous colitis: importance of person to person spread.

  1987cited by this paper
• Clindamycin-Associated Colitis: A Prospective Study

  1974cited by this paper
• INTESTINAL FLORA IN NEW-BORN INFANTS: WITH A DESCRIPTION OF A NEW PATHOGENIC ANAEROBE, BACILLUS DIFFICILIS

  1935cited by this paper

• Oral immunization with engineered probiotics expressing tcdB protects mice against Clostridioides difficile infection.

  2026cites this paper
• Fulminant Clostridioides difficile Infection During Repeated High-Dose Cytarabine Consolidation for Acute Myeloid Leukemia: A Fatal Case.

  2026cites this paper
• SAGES white paper on antibiotic omission in the management of acute uncomplicated diverticulitis: why, when, who, and most importantly, how

  2025cites this paper
• Some Factors Influencing the Number of Clostridioides difficile Spores Detected in Hospital Wastewater

  2025cites this paper
• The Ambivalent Nature of Bacteroides fragilis and the Interaction with Clostridioides difficile: Benefits and Disadvantages for the Human Host

  2025cites this paper
• Proof-of-concept MALDI-TOF-MS assay for the detection of Toxin B enzymatic activity in Clostridioides difficile infection

  2025cites this paper
• Health economic burden of refractory and recurrent Clostridioides difficile infection in the inpatient setting of the German health care system - the IBIS Study.

  2025cites this paper
• The Impact of Obesity on Clostridioides difficile Infection Outcomes: A Retrospective Cohort Study

  2025cites this paper
• Healthcare-Associated Clostridioides difficile Infection: A Hospital-Based Retrospective Study in North Eastern Romania

  2025cites this paper
• Bezlotoxumab for the prevention of recurrent Clostridioides difficile infection for patients with cancer

  2025cites this paper
• Inhibition of Clostridioides difficile-specific DNA adenine methyltransferase CamA by analogs of S-adenosyl-l-methionine

  2025cites this paper
• Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection

  2025cites this paper
• Bioinformatics Approach on Hypothetical Protein from Clostridioides difficile: Structural, Functional and Molecular Docking Analysis

  2025cites this paper
• Risk Factors for Antibiotic Exposure Post–Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Study

  2025cites this paper
• Dominance of toxigenic Clostridioides difficile strains and the appearance of the emerging PCR ribotype 955 in hospitals in Silesia, Poland

  2025cites this paper
• Outcomes of Fecal Microbiota Transplantation for Clostridioides difficile Infection in South Australia

  2025cites this paper
• Integrative Multi-omics Deciphers the Assembly Rules of the Human Skin Microbiome and Highlights Lipid-Mediated Niche Partitioning

  2025cites this paper
• Inhibition of Clostridioides difficile-Specific DNA Adenine Methyltransferase CamA by Analogs of S‑Adenosyl‑l‑methionine

  2025cites this paper
• The antimicrobial peptide Angie 5 inhibits TcdA and TcdB from Clostridioides difficile

  2025cites this paper
• Recent advances of engineered probiotics for therapeutic applications

  2025cites this paper
• Caffeic acid phenethyl ester protects Clostridioides difficile infection by toxin inhibition and microbiota modulation

  2025cites this paper
• Synthetic niclosamide-loaded controlled-release nanospheres with high solubility and stability exerting multiple effects against Clostridioides difficile

  2025cites this paper
• Severe Pseudomembranous Colitis Following Distal Femur Plating: A Case for Early Endoscopic Evaluation Despite Negative Clostridioides difficile Testing

  2025cites this paper
• The challenges and opportunities in the expanding horizons of microbiota transplant therapies

  2025cites this paper
• Clostridioides difficile infection in Saudi Arabia: Prevalence, risk factors, and outcomes in a tertiary hospital setting

  2025cites this paper
• Clostridioides difficile in Children.

  2025cites this paper
• Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study

  2025cites this paper
• Restoration of the Mucosal Barrier by Lactobacillus gasseri HDS0266 and Enterococcus faecium HDS0288 in Dextran Sodium Sulfate and Clostridioides difficile-Induced Colitis Mice.

  2025cites this paper
• Clostridium Butyricum Miyairi Bacteriocin Treatment for Clostridioides difficile Infections with Clinical Isolates: Insights from In Vitro, Ex Vivo, and Mouse Model Studies.

  2025cites this paper
• Clostridioides difficile infection and recurrence in cancer patients (CIRCA): a multicentre, international study.

  2025cites this paper
• Japanese Society for infection prevention and control guide to Clostridioides difficile infection prevention and control.

  2024cites this paper
• Clostridium difficile and gut health: Bacteria, the gut microbiome, and diet

  2024cites this paper
• Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options

  2024cites this paper
• Antimicrobial Resistance and Associated Risk Factors for Clostridium difficile in Patients Attending Tertiary Care Settings

  2024cites this paper
• Inhibition of Clostridioides difficile toxins TcdA and TcdB by the amiodarone derivative dronedarone

  2024cites this paper
• Fecal microbiota live - jslm (Rebyota™/RBL) for management of recurrent Clostridioides difficile infection.

  2024cites this paper
• Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection.

  2024cites this paper
• Improving Clostridioides difficile Infectious Disease Treatment Response via Adherence to Clinical Practice Guidelines

  2024cites this paper
• Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline

  2024cites this paper
• The Impact of Immune System Aging on Infectious Diseases

  2024cites this paper
• A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany

  2024cites this paper
• The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience.

  2024cites this paper
• In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital

  2024cites this paper
• Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism

  2024cites this paper
• Current and Ongoing Developments in Targeting Clostridioides difficile Infection and Recurrence

  2024cites this paper
• The impact of 30-day antecedent antibiotic exposure on C. difficile ribotype patterns and the relationship with clinical outcomes: A single center study.

  2024cites this paper
• Clostridioides difficile infection: an update.

  2024cites this paper
• Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent Clostridioides difficile infection.

  2024cites this paper
• Antibiotic resistance of enteropathogenic bacteria in a teaching hospital in North Khuzestan during a three-year period

  2024cites this paper
• Nonsteroidal anti-inflammatory drugs sensitize epithelial cells to Clostridioides difficile toxin–mediated mitochondrial damage

  2023cites this paper
• Characteristics of Hospitalized Adults 55 and Older With Clostridioides difficile Infection.

  2023influential citation
• A Rare Case of Chronic Photophobia Associated With Oral Vancomycin Therapy: Exploring the Relationship

  2023cites this paper
• The leaky gut and the gut microbiome in sepsis – targets in research and treatment

  2023cites this paper
• Characteristics of Hospitalized Adults 55 and Older With Clostridioides difficile Infection

  2023cites this paper
• The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection – A Systematic Review

  2023cites this paper
• Understanding the mechanisms and translational implications of the microbiome for cancer therapy innovation

  2023cites this paper
• Synthesis of Muramyl‐δ‐Lactam in Spore Peptidoglycan of Clostridioides difficile

  2023cites this paper
• Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis.

  2023cites this paper
• Clostridioides difficile ferrosome organelles combat nutritional immunity

  2023influential citation
• Clostridium difficile Infections in an Emergency Surgical Unit from North-East Romania

  2023cites this paper
• Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective

  2023cites this paper
• Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of Clostridium difficile Infection Associated with Antibacterial Drug Exposure

  2023cites this paper
• Whole Genome Sequencing Evidences High Rates of Relapse in Clostridioides difficile Infection Caused by the Epidemic Ribotype 106

  2023cites this paper
• Design, Synthesis, and Evaluation of Cephamycin-Based Antisporulation Agents targeting Clostridioides difficile.

  2023cites this paper
• Characterizing metabolic drivers of Clostridioides difficile infection with activity-based hydrazine probes

  2023cites this paper
• Clostridium difficile infection in pediatric patients (Review)

  2023cites this paper
• Clostridioides difficile infections; new treatments and future perspectives

  2023cites this paper
• Clinical potential of microbiota in thyroid cancer therapy.

  2023cites this paper
• A Colonic Organoid Model Challenged with the Large Toxins of Clostridioides difficile TcdA and TcdB Exhibit Deregulated Tight Junction Proteins

  2023cites this paper
• Non-viral pathogens of infectious diarrhoea post-allogeneic stem cell transplantation are associated with graft-versus-host disease

  2023cites this paper
• Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).

  2023cites this paper
• Prevention and treatment of C. difficile in cancer patients

  2023cites this paper
• Inhibition of selenoprotein synthesis is not the mechanism by which auranofin inhibits growth of Clostridioides difficile

  2023cites this paper
• CLINICAL OUTCOME AND SEVERITY OF CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE INFECTION AT A TERTIARY REFERRAL HOSPITAL IN BRAZIL.

  2023cites this paper
• ANTIDEPRESSANT MEDICATIONS ARE ASSOCIATED WITH INCREASED RISK OF HOSPITAL-ACQUIRED CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDY.

  2023cites this paper
• p-Cresol Sulfate Is a Sensitive Urinary Marker of Fecal Microbiota Transplantation and Antibiotics Treatments in Human Patients and Mouse Models

  2023cites this paper
• Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy

  2023cites this paper
• Exploring the inhibitory potential of the antiarrhythmic drug amiodarone against Clostridioides difficile toxins TcdA and TcdB

  2023cites this paper
• Short-Chain Fatty Acid Levels after Fecal Microbiota Transplantation in a Pediatric Cohort with Recurrent Clostridioides difficile Infection

  2023cites this paper
• How Would You Manage This Patient With Clostridioides difficile Infection?

  2023cites this paper
• Clostridioides difficile infection drives neuronal inflammation

  2023cites this paper
• The Prevalence and Risk Factors of Clostridioides difficile Infection in Inflammatory Bowel Disease: 10-Year South Korean Experience Based on the National Database

  2023cites this paper
• Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort

  2022cites this paper
• Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).

  2022cites this paper
• A Case of Clostridioides difficile Infection of a Pregnant Woman Treated with Colectomy

  2022cites this paper
• Fecal microbiota transplantation across the lifespan: balancing efficacy, safety, and innovation.

  2022cites this paper
• Application and development of fecal microbiota transplantation in the treatment of gastrointestinal and metabolic diseases: A review

  2022cites this paper
• Peroxisome proliferator-activated receptor-γ as the gatekeeper of tight junction in Clostridioides difficile infection

  2022cites this paper
• Isolation, molecular typing and antimicrobial resistance of Clostridium difficile in dogs and cats in Lanzhou city of Northwest China

  2022cites this paper
• Prevalence and antimicrobial resistance pattern of Clostridium difficile among hospitalized diarrheal patients: A systematic review and meta-analysis

  2022cites this paper
• Screening for effective cell-penetrating peptides with minimal impact on epithelial cells and gut commensals in vitro

  2022cites this paper
• Inhibition of Arp2/3 Complex after ADP-Ribosylation of Arp2 by Binary Clostridioides Toxins

  2022cites this paper
• Severe Clostridioides difficile Infection in the Intensive Care Unit-Medical and Surgical Management.

  2022cites this paper
• Factores asociados a brote por Clostridium difficile en el Hospital Nacional de Geriatría y Gerontología, Costa Rica

  2022cites this paper
• Evaluation of Derivatives of (+)-Puupehenone against Clostridioides difficile and Other Gram-Positive Bacteria

  2022cites this paper
• Effectiveness and safety of colonic and capsule fecal microbiota transplantation for recurrent Clostridioides difficile infection.

  2022cites this paper
• Clostridioides difficile Infection Treatment and Outcome Disparities in a National Sample of United States Hospitals

  2022cites this paper
• Melatonin as an Antimicrobial Adjuvant and Anti-Inflammatory for the Management of Recurrent Clostridioides difficile Infection

  2022cites this paper
• The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660

  2022cites this paper
• From signal transduction to protein toxins—a narrative review about milestones on the research route of C. difficile toxins

  2022cites this paper